Infant series, school-entry booster, and a booster every 10 years.
QUADRACEL is listed under Health Canada DIN 02534789. The product record and monograph below describe this formulation; the dose schedule comes from the Canadian Immunization Guide.
At a glance
Brand
QUADRACEL
DIN
02534789
Vaccine
DTaP-IPV
Presentation
0.5 mL · suspension · intramuscular · 4 to 6 years
Live vaccine
No
Age and suitability depend on the product, the person and the reason for vaccination. Use the planner for a starting point and confirm with a healthcare professional.
Official sources
Use the DIN to confirm this exact product in Health Canada's Drug Product Database.
A listed product may not be stocked or publicly funded.
Before and after your vaccination
Bring your immunization record if you have one, so earlier doses can be checked.
Tell the healthcare professional about a serious reaction to a previous vaccine or an ingredient, and mention any health conditions or medicines that could affect your vaccination.
After the dose, stay where you can be observed for at least 15 minutes. Tell someone right away if you feel faint or develop symptoms of an allergic reaction.
Keep a record of the vaccine name, date and dose you received.
For product-specific effects and precautions, check this DIN in the Health Canada product record and monograph. The general appointment steps above apply to all vaccinations.
No directly matching Pharmasist product guide was identified for this DIN. Use the linked Health Canada record to check your exact product.
Dose schedules
These are Canadian Immunization Guide schedules associated with this DIN. The right schedule depends on age, health, prior doses and reason for vaccination. Public health recommendations may differ from a product monograph's authorized schedule.
DTaP-IPV — school-entry booster (4 to 6 years)
1 dose
Single booster dose at 4 to 6 years of age.
DTaP-IPV or Tdap-IPV as the booster for children 4 to 6 years of age who completed the infant series. Not needed if the fourth infant dose was given at 4 years of age or older.
Family guidance on pregnancy: Tdap is recommended in every pregnancy, irrespective of immunization history, ideally at 27 to 32 weeks. Polio (IPV) may be considered for a non-immune person at increased risk; Hib when a predisposing condition is present.
Family guidance on breastfeeding: Tdap is recommended if no adult dose has been given; polio and Hib are used if indicated.
General information only. A suggested date is not an appointment or a prescription; a healthcare professional confirms what you need. Clinical rules reviewed on 2026-09-27.